<?xml version="1.0" encoding="UTF-8"?>
<p id="p0250">
 <bold>Anosmia and Ageusia</bold>, the prevalence of anosmia and ageusia ranges widely in different studies from 5% in a study from China [
 <xref rid="bb0195" ref-type="bibr">39</xref>] to about 88% in an Italian study [
 <xref rid="bb0280" ref-type="bibr">56</xref>]. Smell impairment was also reported in SARS-CoV-1 and influenza infections. [
 <xref rid="bb0135" ref-type="bibr">27</xref>] Anosmia was reported in 3730 patients out of 28 studies in the case of SARS-CoV-2. (
 <xref rid="t0015" ref-type="table">Table 3</xref>) In COVID-19, anosmia is typically not accompanied by nasal swelling or rhinitis and based the findings of several studies it is an important common early clinical presentation even in the absence of other respiratory symptoms. [
 <xref rid="bb1045" ref-type="bibr">209</xref>] several studies reported that anosmia was more common among females, younger and non-hospitalized patients. [
 <xref rid="bb1055" ref-type="bibr">211</xref>,
 <xref rid="bb1070" ref-type="bibr">214</xref>] In most patients, anosmia went away on its own within 3 weeks. [
 <xref rid="bb1055" ref-type="bibr">211</xref>]
</p>
